Compare Bristol-Myers Squibb Co (BMY) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance

Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.

BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.

VTI trades at $381.95, up 0.08% today, with a bullish technical signal driven by moving averages, though oscillators are neutral and RSI levels suggest overbought conditions. The ETF offers broad diversification with over 3,500 holdings and a low 0.03% expense ratio, as noted by The Motley Fool on August 11, 2026. Recent institutional activity includes mixed buying and selling, with a dividend scheduled for June 30, 2026.

Outlook remains positive for long-term investors due to low costs and market-wide exposure, but risks include market volatility and concentration in large-cap tech. Analyst sentiment is generally favorable, emphasizing VTI's role in foundational portfolios, though current high RSI levels indicate potential near-term pullbacks.